Literature DB >> 33533919

Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers.

Fabienne Bejjani1,2, Claire Tolza1, Mathias Boulanger1, Damien Downes3, Raphaël Romero4,5, Muhammad Ahmad Maqbool1, Amal Zine El Aabidine1, Jean-Christophe Andrau1, Sophie Lebre4, Laurent Brehelin5, Hughes Parrinello6, Marine Rohmer6, Tony Kaoma7, Laurent Vallar8, Jim R Hughes3, Kazem Zibara2,9, Charles-Henri Lecellier1,5, Marc Piechaczyk1, Isabelle Jariel-Encontre1.   

Abstract

The ubiquitous family of dimeric transcription factors AP-1 is made up of Fos and Jun family proteins. It has long been thought to operate principally at gene promoters and how it controls transcription is still ill-understood. The Fos family protein Fra-1 is overexpressed in triple negative breast cancers (TNBCs) where it contributes to tumor aggressiveness. To address its transcriptional actions in TNBCs, we combined transcriptomics, ChIP-seqs, machine learning and NG Capture-C. Additionally, we studied its Fos family kin Fra-2 also expressed in TNBCs, albeit much less. Consistently with their pleiotropic effects, Fra-1 and Fra-2 up- and downregulate individually, together or redundantly many genes associated with a wide range of biological processes. Target gene regulation is principally due to binding of Fra-1 and Fra-2 at regulatory elements located distantly from cognate promoters where Fra-1 modulates the recruitment of the transcriptional co-regulator p300/CBP and where differences in AP-1 variant motif recognition can underlie preferential Fra-1- or Fra-2 bindings. Our work also shows no major role for Fra-1 in chromatin architecture control at target gene loci, but suggests collaboration between Fra-1-bound and -unbound enhancers within chromatin hubs sometimes including promoters for other Fra-1-regulated genes. Our work impacts our view of AP-1.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33533919      PMCID: PMC7968996          DOI: 10.1093/nar/gkab053

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  82 in total

1.  Transformation by ras modifies AP1 composition and activity.

Authors:  F Mechta; D Lallemand; C M Pfarr; M Yaniv
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

Review 3.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

Review 4.  CTCF: a Swiss-army knife for genome organization and transcription regulation.

Authors:  Luca Braccioli; Elzo de Wit
Journal:  Essays Biochem       Date:  2019-04-23       Impact factor: 8.000

5.  Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein.

Authors:  F Talotta; T Mega; G Bossis; L Casalino; J Basbous; I Jariel-Encontre; M Piechaczyk; P Verde
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

6.  Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.

Authors:  A E Sayan; R Stanford; R Vickery; E Grigorenko; J Diesch; K Kulbicki; R Edwards; R Pal; P Greaves; I Jariel-Encontre; M Piechaczyk; M Kriajevska; J K Mellon; A S Dhillon; E Tulchinsky
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

Review 7.  The Fos family of transcription factors and their role in tumourigenesis.

Authors:  Karin Milde-Langosch
Journal:  Eur J Cancer       Date:  2005-09-30       Impact factor: 9.162

Review 8.  Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals.

Authors:  Anne K Voss; Tim Thomas
Journal:  Bioessays       Date:  2018-08-24       Impact factor: 4.345

9.  The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation.

Authors:  S J Cook; N Aziz; M McMahon
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Multi-enhancer transcriptional hubs confer phenotypic robustness.

Authors:  Albert Tsai; Mariana Rp Alves; Justin Crocker
Journal:  Elife       Date:  2019-07-11       Impact factor: 8.140

View more
  4 in total

1.  The histone variant macroH2A1.1 regulates RNA polymerase II-paused genes within defined chromatin interaction landscapes.

Authors:  Ludmila Recoules; Alexandre Heurteau; Flavien Raynal; Nezih Karasu; Fatima Moutahir; Fabienne Bejjani; Isabelle Jariel-Encontre; Olivier Cuvier; Thomas Sexton; Anne-Claire Lavigne; Kerstin Bystricky
Journal:  J Cell Sci       Date:  2022-04-11       Impact factor: 5.235

2.  A systematic comparison of FOSL1, FOSL2 and BATF-mediated transcriptional regulation during early human Th17 differentiation.

Authors:  Ankitha Shetty; Subhash Kumar Tripathi; Sini Junttila; Tanja Buchacher; Rahul Biradar; Santosh D Bhosale; Tapio Envall; Asta Laiho; Robert Moulder; Omid Rasool; Sanjeev Galande; Laura L Elo; Riitta Lahesmaa
Journal:  Nucleic Acids Res       Date:  2022-05-20       Impact factor: 19.160

3.  CREBBP knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer.

Authors:  Haoyang Hu; Sheng Yin; Ruyue Ma; Rujun Chen; Shuqing Li; Yaping Chen; He Fei; Lina Yang
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

Review 4.  The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.

Authors:  Laura Casalino; Francesco Talotta; Amelia Cimmino; Pasquale Verde
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.